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Esophagus
K.V. Veerendra Kumar, Ramesh Sagar and Joseph Mathew
Abstract
Esophageal cancer, according to GLOBOCAN 2018 data, ranks seventh in terms 
of incidence and sixth in mortality among all cancers worldwide. In India, it is 
considered the fourth most common cause of cancer-related deaths. Influenced by 
lifestyle, socioeconomic and environmental factors, striking geographic variations 
in incidence exist. With regard to histopathology, esophageal cancers are unique 
among malignancies of the gastrointestinal tract in that they principally comprise 
two variants: squamous cell carcinoma (SCC) and adenocarcinoma, with the 
former accounting for up to 80% of cases. Etiological factors for SCC show marked 
variations worldwide, with tobacco consumption, alcohol, hot beverages, and poor 
nutrition constituting the predominant predisposing factors. Although present day 
therapeutic interventions have begun to positively influence disease prognosis, with 
significant improvements in survival noted over the last 3 decades, cancer of the 
esophagus remains a highly lethal disease with a case fatality rate approaching 90%. 
Management of this disease includes all three primary modalities of treatment; 
surgery, chemotherapy and radiotherapy. Surgical resection, the only curative 
modality of treatment, remains a challenge even with advances like minimal access 
surgery and is feasible only in early stage disease. Early diagnosis and accurate stag-
ing are paramount for optimizing treatment and hence, prognosis.
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1. Introduction
Despite a better understanding of the biology of disease and a number of 
advances in diagnostic and therapeutic interventions, cancer of the esophagus 
remains a highly aggressive and lethal malignancy.
According to GLOBOCAN 2018 data, this disease ranks seventh in terms of 
cancer incidence (572,000 new cases) and sixth in overall cancer-related mortality 
(509,000 deaths), signifying that esophageal cancer was accountable for an esti-
mated 1 in every 20 cancer-related deaths in 2018 [1]. In India, esophageal cancer is 
the fourth most common cause of cancer-related deaths.
Although advances in therapeutic interventions have begun to have a positive 
impact on survival evident over the past 3 decades, esophageal cancer remains a 
formidable disease with a case fatality rate of 90% [2].
Histopathologically, cancers of the esophagus are primarily of two types, 
squamous cell carcinoma (SCC) and adenocarcinoma. Marked geographic variation 
in incidence and cancer type has been known to occur and is influenced by life style, 
socioeconomic and environmental factors [3].
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Part of 
esophagus
Extent Distance from upper 
incisor (cm)
Cervical 
esophagus
Pharyngoesophageal junction to thoracic inlet 18
Upper thoracic Thoracic inlet to the lower border of T6 vertebra 26
Mid thoracic Lower border of T6 to lower border of T8 vertebra 31
Lower esophagus Lower border of T8 to cardiac orifice 40
Table 1. 
Parts of the esophagus according to UICC (1978).
Alcohol consumption and smoking and the synergistic effects thereof are major 
risk factors for the development of SCC in the West. The incidence of esophageal 
adenocarcinoma in the West has seen a steep rise in the past 20 years, surpassing 
SCC as the most common type of esophageal cancer [4].
In India, squamous cell carcinoma accounts for up to 80% of all cases of esopha-
geal cancers. Data from Kidwai Cancer Institute and Tata Memorial Hospital show 
that SCC of the esophagus is the second most common cancer among men and the 
fourth leading cause of cancer mortality. Although etiological factors implicated 
in SCCs show marked regional variation in different parts of India, tobacco con-
sumption in various forms, alcohol, hot beverages, and poor nutrition remain the 
predominant predisposing factors in the subcontinent.
Despite the two pathological subtypes having different etiologic factors, biology 
and prognostic profiles, they have often been managed as a single entity. Today, 
management of esophageal cancer includes all three modalities of treatment, i.e., 
surgery, chemotherapy and radiotherapy. Considering that the esophagus spans three 
anatomic compartments: the neck, the thorax and the abdomen and its proximity 
to vital structures, surgery of this organ remains a challenge even with present -day 
therapeutic advances such as minimal access surgery. Surgery is the only curative 
therapeutic modality. However, its applicability is restricted to the early stages of the 
disease [5–7].
Most patients with esophageal cancer, on account of late onset of symptoms and 
a consequential delay in the final diagnosis, present with advanced disease which 
precludes definitive surgical intervention. Hence, the prognosis in general remains 
poor [5, 8]. Early diagnosis and accurate staging are considered vital for the optimal 
management of esophageal cancer.
2. Anatomy
The esophagus is a muscular tube beginning from the cricopharyngeal sphinc-
ter at the cricoid cartilage at the level of the sixth cervical vertebra and terminat-
ing at the gastroesophageal junction at the level of the 11th thoracic vertebra. It 
travels through the neck, chest and upper abdomen, and is anatomically divided 
into the cervical, the thoracic, and the abdominal segments [9] (Table 1). From 
its origin at the cricoid cartilage to the gastroesophageal junction, the length 
of the adult esophagus varies from 22 to 28 cm with the distal 3 cm lying intra-
abdominally [10].
The cervical esophagus lies just left of the midline and is closely related to the 
trachea anteriorly and the prevertebral fascia posteriorly. Only a minimal amount of 
loose areolar tissue separates the trachea from the esophagus and malignancies are 
known to spread from the esophagus to the trachea and vice versa [11]. The upper 
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portion of the thoracic esophagus curves slightly to the right and passes behind the 
tracheal bifurcation and the left main-stem bronchus. On either side of the thoracic 
esophagus are the lungs with their pleural linings. Additionally, the azygos vein, 
arching over the right main bronchus to drain into the superior vena cava, and the 
subclavian artery are important relations on the right. On the left are the aortic arch 
and the aorta which assumes a posterior course in relation to the esophagus. The lower 
portion of thoracic esophagus runs behind the pericardium and the left atrium, where 
it bends to the left to enter the abdomen through the esophageal hiatus. The left lobe 
of the liver bears an anterior relation to the abdominal esophagus [12].
There are three areas of physiological/normal narrowing of the esophageal 
lumen: at the cricoid cartilage, at the point where it crosses the left main bronchus 
and the aortic arch and at the diaphragmatic hiatus.
2.1 Supports of the esophagus.
The outer longitudinal muscular layer of the esophagus inserts into the posterior 
ridge of the cricoid cartilage via the cricoesophageal tendon. The inner circular 
muscle layer is in continuity with the inferior laryngeal constrictor which inserts on 
the sphenoid. Bronchoesophageal and pleuroesophageal strands are fibromuscular 
bands which connect the esophagus with the trachea and bronchi and pleura, 
respectively. Inferiorly, the posterior gastric ligaments and the lesser omentum are 
the main anchors of the distal esophagus, the phrenoesophageal membrane serving 
as a weaker support [12].
The peritoneal reflections associated with the esophagus are the hepatogastric 
ligament and the gastrosplenic ligament. The former encloses the left gastric ves-
sels, the hepatic division of the left vagal trunk and lymph nodes. The hepatogastric 
ligament continues to the left of the abdominal esophagus as the gastrosplenic 
ligament. The lesser sac lies posterior to these ligaments [10, 12].
2.2 Blood supply of esophagus
The esophagus has a segmental blood supply. The cervical esophagus is pre-
dominantly supplied by the inferior thyroid artery, the upper and mid thoracic 
esophagus by branches from the bronchial arteries and the descending thoracic 
aorta and the lower thoracic and intra-abdominal esophagus by branches from the 
left gastric and inferior phrenic arteries [13].
An extensive submucosal venous plexus communicates with the longitudinally 
oriented periesophageal veins through the muscularis. In the cervical esophagus, 
these veins drain principally into the inferior thyroid veins, in the thoracic esopha-
gus into the azygos vein and in the abdominal esophagus, into the azygos and left 
gastric veins. Hence, in the distal esophagus, the caval and portal venous system 
are connected through the submucosal plexus. A rise in portal venous pressure can 
transform these submucosal veins into varices as is seen in portal hypertension [14].
Lymphatics form a dense submucosal plexus which runs along the long axis of the 
esophagus. Lymph flows primarily along the long axis of the esophagus the direc-
tion of which is cephalad in the proximal two thirds of the esophagus and caudad 
in the distal third. Nevertheless, a definitive watershed line for the demarcation of 
lymphatic drainage is not evident: lymph can course freely along the entire length 
of the esophagus via the esophageal plexus before draining into the regional nodes. 
This lymphatic network serves as a means for the spread of cancer intramurally. 
Consequently, cancers of the upper esophagus can metastasize to the superior gastric 
nodes or cancers of the lower esophagus to the superior mediastinal nodes. The 
submucosal plexus gives off branches which communicate with the peri-oesophageal 
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lymph plexus which then drains into the posterior mediastinal nodes. Again, these 
nodes can drain into both the supraclavicular and the left gastric nodes [12].
In general, lymph from the upper esophagus drains mostly into the cervical and 
paratracheal nodes and that from the lower thoracic and abdominal esophagus into 
the retrocardiac and celiac nodes.
3. Histology
The mucosal lining of the esophagus comprises a thick layer of stratified squa-
mous non-keratinizing epithelium. Proximally, it is continuous with the mucosa 
of the oropharynx. Histologically, the gastroesophageal junction is delineated by 
an irregular line (the “Z line”) between the stratified squamous epithelium proxi-
mally and the simple columnar epithelium distally. However, patches of gastric 
epithelium can be found proximal to the squamocolumnar junction. Deep to the 
mucosal lining are the lamina propria and the muscularis mucosa. The submucosa 
is a layer of connective tissue layer that lies deep to the mucosa. It contains small 
vessels, lymphatics, nerves and mucous glands. The submucosa is widely consid-
ered the strongest layer of the esophageal wall. Meissner’s nerve plexus is found in 
the submucosa [10, 15].
The tunica muscularis comprises two layers; the external or longitudinal muscle 
layer and the inner circular muscle layer both beginning at the level of the cricoid 
cartilage. Auerbach’s plexus lies in the connective tissue between the circular and 
longitudinal muscular layers.
The musculature of the pharynx and proximal esophagus is striated and is gradu-
ally replaced by involuntary smooth muscle in the distal esophagus reflecting the 
embryonic development of the esophagus. The lower esophageal sphincter although 
not an anatomically defined sphincter is a high pressure zone which serves to prevent 
acid reflux into the esophagus. The tunica adventitia is the outermost thin layer of 
loose areolar tissue. It contains small vessels, lymphatics and nerves. The esophagus 
lacks a serosal lining; anastomotic dehiscence following esophageal resection and 
anastomosis has been attributed to this absence of this outermost layer [15].
4. Embryology
The esophagus develops from the foregut of the primitive endodermal tube 
which is embryological precursor of the gastrointestinal tract. The foregut starts 
to divide into the laryngotracheal and the oesophageal tubes in the fourth week 
of gestation. Failure of division may result in congenital anomalies ranging from 
esophageal atresia to tracheo-oesophageal fistulae. Distal to the oesophageal tube, 
the foregut dilates to form the stomach [10].
Cephalad to the aortic arch, the esophageal musculature is derived from the 
branchial arches whereas caudal to the aortic arch, the embryonic esophagus is 
suspended in a mesentery, similar to the rest of the foregut [10]. Hence, the tunica 
muscularis of the upper third of the esophagus comprises skeletal muscle whereas 
that of the middle and lower third is predominantly smooth muscle.
5. Physiology
The esophagus primarily serves as a conduit to convey food through the thoracic 
cage.
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Swallowing may be divided into three phases. The oral phase is voluntary 
and results in the food bolus entering the pharynx. The pharyngeal phase is 
involuntary and initiates a peristaltic wave propelling food through the upper 
oesophageal sphincter.
The esophageal phase is a continuation of the peristaltic wave initiated by the 
superior constrictor in the pharynx into the esophagus allowing the bolus to reach 
the stomach. Failure to do so results in esophageal distension which triggers second-
ary peristalses.
The lower esophageal sphincter is primarily a physiologic sphincter. The high 
pressure (15–25 mmHg) in this region serves to prevent the reflux of gastric juices 
into the esophagus. Other factors contributing to the functionality of the LES are 
the diaphragmatic crura, the gastric sling fibers, the valvular effect of the gastro-
esophageal angle and the positive intra-abdominal pressure. Gastroesophageal 
reflux disease is considered a predisposing factor for the development of adenocar-
cinoma of the esophagus [16–18].
6. Biology of esophageal cancer
Esophageal cancer shows marked variations in incidence, histopathologi-
cal type of malignancy according to gender, ethnicity and geographic location. 
Environmental and socioeconomic factors also play a key role in carcinogenesis [3].
The two main histopathologic types of esophageal cancer are squamous cell 
carcinoma and adenocarcinoma. Other uncommon variants include squamous cell 
carcinoma with sarcomatous features, mesenchymal tumors, adenoid cystic carci-
noma, mucoepidermoid carcinoma, neuroendocrine cancer and benign tumors.
The incidence of esophageal adenocarcinoma in Europe and in the United States 
has seen a steep rise in the past 2 decades, surpassing SCC as the most common type 
of esophageal cancer [4]. The rate of SCC of the esophagus has remained relatively 
stable or has seen a declining trend in Western countries [19–21]. Predisposing 
factors include gastroesophageal reflux disease and the ensuing Barrett’s esophagus, 
obesity and smoking [20].
Nevertheless, squamous cell carcinoma remains the most common variety 
of esophageal cancer worldwide, arising as a result of long standing irritation of 
esophageal lining most commonly due to smoking and alcohol abuse, and occu-
pational exposure. Tobacco and alcohol are strong, synergistic risk factors for the 
development of SCC [22]. Other notable predisposing factors are caustic injury, 
Plummer Vinson syndrome and achalasia cardia [20]. Squamous cell carcinomas of 
the esophagus are most likely to arise in the upper and middle thirds of the esopha-
gus whereas esophageal adenocarcinomas are most common in the distal aspect of 
the esophagus.
7. Etiology of SCC
7.1 Environmental promoters of carcinogenesis
7.1.1 Alcohol
Alcohol abuse is a known risk factor for the development of esophageal. 
SCC more so when ingestion exceeds 170 g/week. This risk increases in a linear 
fashion with increasing consumption [23]. Key mechanisms in carcinogen-
esis include metabolic activation and decreased detoxification of potential 
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carcinogens, and increased cellular exposure to oxidants, a critical determinant 
of DNA damage. Also, production of acetaldehyde is increased, leading to 
diminished methyl transferase activity. The risk is compounded by synchronous 
exposure of tobacco [24].
7.1.2 Tobacco
Tobacco smoke contains polycyclic aromatic hydrocarbons, N-nitroso com-
pounds, epoxides, lactones and tar, all of which are known carcinogens. They are 
irritant to the squamous epithelial lining of the esophagus and can give rise to 
metaplasia, a precursor of malignancy, on chronic exposure. Smoking is consid-
ered a risk factor for the development of both esophageal adenocarcinoma and 
SCC. Smoking was shown to contribute to a 12-fold greater incidence of atypical 
nuclei and a two-fold increase in incidence of in situ carcinoma within the basal 
layer of esophagus. Smokers have a nine-fold higher risk of developing SCC when 
compared to nonsmokers (hazard ratio 9.3; 95% CI: 4.0–21.3) [25, 26].
7.1.3 Nitrosamines
The human body is constantly exposed to N-nitrosamines at levels of 
20–200 mcg/day. Nitrates and nitrites are precursors to N-nitroso compounds. 
These compounds are transformed in vivo into alkylating electrophiles that 
form adducts with DNA, by alkylating the N7 and O6 positions of guanine in the 
DNA helix.
7.1.4 Vitamin and mineral deficiency
Deficiencies of vitamins A, C, E and the B complex vitamins such as cyanoco-
balamine, riboflavin and folic acid may predispose to the development of squamous 
cell carcinoma of the esophagus. Among the micronutrients, zinc deficiency can 
induce carcinogenesis by the formation of O6-methylguanine DNA adducts by 
microsomal activation of N-nitrosomethyl-benzylamine. The trace element molyb-
denum is considered protective against the development of esophageal cancer by 
inhibiting the formation of nitrate reductases.
Selenium as an antioxidant plays a role in the inhibition of cell membrane lipid 
peroxidation. Deficiencies in these micronutrients have been linked to an increased 
risk of developing SCC of the esophagus [27–29].
7.1.5 Food and water contaminants
Fungi such as Fusarium, Alternaria, Geotrichium, Aspergillus, Cladosporium, 
and Penicillium have been associated with the development of esophageal cancer 
either by a direct mutagenic effect or through the formation of nitrosamines.
Other rarer causes of esophageal SCC are Helicobacter pylori infection, 
Plummer Vinson syndrome, caustic injury, achalasia cardia and human papillo-
mavirus infection. HPV infection may account for as much as a third of all cases of 
esophageal cancer in high incidence areas as seen in Asia and South Africa [30, 31].
Barrett’s esophagus, longstanding GERD and obesity are considered exclusive risk 
factors for the development of esophageal adenocarcinoma apart from other factors 
such as smoking, socioeconomic status, deficiency in dietary micronutrients which are 
also associated with SCC of the esophagus. Chronic gastroesophageal reflux leads to 
columnar metaplasia of the distal esophagus (Barrett’s esophagus) which is associated 
with a 30- to 40-fold increased risk of progressing to esophageal adenocarcinoma [25].
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7.2 Molecular oncogenesis
Epidermal growth factor (EGF) is an autocrine growth factor whose DNA is 
amplified in esophageal SCC. Overexpression of mRNA and the protein product 
appears to decrease survival. EGF receptor gene is the homolog of erb-B oncogene. 
The overexpression of the epidermal growth factor correlates with an increased 
frequency of lymph node metastasis [32].
Transforming growth factor-alpha is another autocrine growth factor that is 
co expressed with EGF and EGF receptor gene. They code for proteins that are 
homologous to EGF. The co-amplification correlates with advancing clinical stage 
and a worse prognosis in esophageal SCC [32, 33].
Ras encodes a protein product, p21, and has homology to G-proteins; a critical 
aspect of the signal transduction cascade. Over expression of p21 has been observed 
in esophageal SCC.
Tumor suppressor genes inhibit uncontrolled growth. They are necessary for 
repair to take place before damaged DNA is replicated. Gene inactivation in chro-
mosome 17p is detected in at least half of esophageal cancers. PCR amplification 
and direct sequencing may detect p53 mutation in one third of specimens.
Human papilloma virus has been associated with the development of esophageal 
cancer. Low risk HPV genotypes are HPV 6 and 11.high risk genotypes are HPV 16, 
18, and 33 [31].
Geographic distribution of esophageal squamous cell carcinoma SCC of the 
esophagus is the most common histologic type of esophageal cancer outside 
Western countries, where adenocarcinoma predominates. Incidence rates in 
China and some parts of Africa are estimated to be as high as 140 per 100,000 
population [34]. Men and women are affected equally in these high-incidence 
areas [25]. However, in the United States and Europe, the incidence is much 
lower, estimated to be around 3 cases per 100,000 population with a declining 
trend [34].
8. Screening and early detection
Despite several potential preventive measures, none have been proven to 
decrease the risk of esophageal carcinoma in prospective well-designed trials [23]. 
The relatively low incidence of disease, absence of symptoms in the early stage, and 
the rarity of hereditary forms make population-based screening untenable except in 
certain high-risk areas of the world [35].
9. Diagnosis
The management of esophageal cancer remains a challenge even today because 
of the late stage at presentation of the majority and the overall poor prognosis of 
disease. It is estimated that only one in eight esophageal cancers are identified at 
an early stage (T1). These include cancers diagnosed incidentally during a gastros-
copy performed for other reasons or during the course of surveillance programs. 
However, most esophageal cancers are diagnosed after symptoms develop. Typical 
symptoms which prompt patients to seek medical attention include dysphagia 
(which signifies a 50% reduction in the esophageal lumen) [36], vomiting, loss 
of body weight, and gastrointestinal bleeding. In general, these are manifested in 
tumors that are locally advanced and hence, inoperable. Moreover, unlike esopha-
geal adenocarcinoma, which evolves from premalignant conditions such as Barrett’s 
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esophagus in the background of gastroesophageal reflux disease, SCC lacks a 
premalignant stage. Hence, they tend to present at an advanced stage.
Gastroscopy remains the investigation of choice for the diagnosis of esophageal 
cancer as it permits the visualization of mucosal abnormalities and enables retrieval 
of tissue for histopathological examination. If erosions, ulcers, or strictures are 
found, the endoscopist decides whether these changes are neoplastic or not and 
whether they necessitate a biopsy. Dysplastic signs are discolorations, fine granu-
lated surfaces (orange peel effect), as well as small elevations and troughs.
The sensitivity of endoscopy in detecting early-stage carcinoma may be 
improved by adjunctive techniques such as chromoendoscopy (using 1.5–3% acetic 
acid for adenocarcinoma and 0.5–1% Lugol’s solution for SCC) or virtual chromo-
endoscopy which serves to highlight foci that are suspicious for malignancy.
A ‘targeted’ biopsy may be obtained from these areas for confirmation [37]. The 
current recommendation with respect to diagnostic tissue sampling in esophageal 
cancer is that a minimum of eight samples be taken from the lesion specifically from 
the margins and center; sensitivity for biopsies in detecting esophageal cancer has 
been shown to be 96% when multiple samples are taken from the lesion in question 
[37]. Alternatively, a diagnostic endoscopic mucosal resection may be performed [38].
Preoperative assessment and staging of esophageal SCC As in any malignancy, 
accurate staging is crucial for optimizing treatment in esophageal cancer. The depth 
of the tumor determines the feasibility of endoscopic management.
Several imaging techniques have been employed in the preoperative staging of 
these patients [39–45]. These include endoscopic ultrasonography (EUS), computed 
tomography (CT) and magnetic resonance imaging (MRI) among others. However, 
all these modalities have their limitations.
Numerous studies have demonstrated the superiority of EUS in both local tumor 
(T) and nodal (N) staging over CT [46]. EUS is the ideal modality for assessing the 
depth of invasion of the primary tumour with accuracy for T staging approaching 
90% in superficial and partially obstructing esophageal cancers [47]. However, 
accuracy declines in cases of completely obstructing tumors wherein the luminal 
compromise associated with disease cannot be negotiated by the echo-endoscope 
[47–50]. This is considered the major limitation of this technique and precludes 
accurate staging in 16–50% of esophageal cancer patients [49–50]. Also, its ability 
to discriminate between subtle differences in T1 disease, that is, T1a versus T1b, is 
less exact [51]. For assessing regional lymph node metastases, EUS is reported to 
be more sensitive but less specific than CT and hence carries a risk of over-staging 
[48, 49]. Endosonographic characteristics of a malignant lymph node include 
size >10 mm, round and smooth features, proximity to the primary tumor, and 
hypoechogenicity. The accuracy of EUS for nodal staging based solely on these 
criteria approaches 80% [52, 53]. Accuracy of nodal staging can be increased to 
92–98% when FNA of the lymph node is performed concurrently with EUS [53, 54]. 
However, false positive results, as a result of contamination by exfoliated cancer 
cells from the primary tumor site, are a possibility when EUS guided FNAC of 
suspicious nodes is performed [55].
EUS is not indicated for the evaluation of distant lymph node metastases, where 
CT is preferred [49]. Other limitations associated with EUS are its limited avail-
ability and operator dependence for accurate staging. With respect to its ability to 
provide accurate staging information after neoadjuvant therapy, EUS is not consid-
ered reliable due to the presence of post-treatment adherence and fibrosis [56].
To date, MRI has not gained widespread acceptance for the locoregional staging 
of cancers of the esophagus. Despite initial data [57] suggesting inferiority of MRI 
when compared to CT with respect to accuracy in staging esophageal malignancies, 
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subsequent literature [58] reported that the two modalities were comparable when 
assessing resectability of carcinomas of the esophagus. Nevertheless, CT remains 
the most widely used imaging modality on account of its utility in detecting meta-
static disease and greater availability. Moreover, a CT scan also provides useful 
information regarding extension of the tumor especially with regard to involvement 
of the trachea or the aorta (T4b disease). Suspicion of direct invasion of the thoracic 
aorta or the tracheobronchial tree should be confirmed with MRI and bronchos-
copy, respectively.
An abdominal ultrasound or preferably, a multi-slice CT scan of the thorax and 
abdomen are required for metastatic evaluation of the tumour before definitive 
therapy is initiated.
FDG-PET scan provides the most accurate information regarding potential 
metastatic disease, increasing the accuracy of detecting occult metastasis by as 
much as 20% over CT alone [59]. Also, FDG-PET is considered a reliable imaging 
modality for post-treatment reassessment and to assess the response to neoadjuvant 
therapy [60]. However, its specific indication and role in this scenario is yet to be 
defined [61].
AJCC 8th Edition [62]
TNM clinical classification—squamous cell carcinoma and adenocarcinoma
T—primary tumour
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement 
membrane
T1 Tumour invades lamina propria, muscularis mucosae, or submucosa
T1a Tumour invades lamina propria or muscularis mucosae
T1b Tumour invades submucosa
T2 Tumour invades muscularis propria
T3 Tumour invades adventitia
T4 Tumour invades adjacent structures
T4a Tumour invades pleura, pericardium, azygos vein, diaphragm, or
T4b peritoneum Tumour invades other adjacent structures such as aorta, vertebral body or trachea
N—regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in 1–2 regional lymph nodes
N2 Metastasis in 3–6 regional lymph nodes
N3 Metastasis in 7 or more regional lymph nodes
M—distant metastasis
M0 No distant metastasis
M1 Distant metastasis
Definition of histologic grade (G)—squamous cell carcinoma and adenocarcinoma
GX Grade cannot be assessed
G 1 Well differentiated
G2 Moderately differentiated
Squamous Cell Carcinoma - Hallmark and Treatment Modalities
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G3 Poorly differentiated, undifferentiated
Stage and prognostic group
Clinical stage
Stage 0 Tis N0 M0
Stage I T1 N0, N1 M0
Stage II T2 N0, N1 M0
T3 N0 M0
Stage III T1,T2 N2 M0
T3 N1, N2 M0
Stage IVA T4a,T4b N0, N1, N2 M0
Stage IVA Any T N3 M0
Stage IVB Any T Any N M1
10. Treatment
10.1 Early stage cancer
Early esophageal cancer as an entity, according to the AJCC seventh edition, 
comprises all high grade dysplastic lesions and T1 malignancies [62]. Presence 
of intraepithelial malignant cells without a breach in the basement membrane is 
termed high grade dysplasia. T1 lesions include malignancies involving the mucosa 
(T1a) and submucosa (T1b) but not invading the muscularis propria.
In order to facilitate greater precision in staging and to further optimise stage-
specific treatment in early esophageal cancer, T1a and T1b lesions have been further 
categorized into three subtypes (M1–M3 and SM1–SM3, respectively) according 
to the depth of invasion. Endoscopic mucosal resection is considered feasible in 
cancers involving the upper third of the submucosa (SM1 lesions) [63–66].
10.1.1 High grade dysplasia and T1a lesions
In cancers confined to the mucosal layer, the risk of lymph nodal disease cor-
relates with the depth of tumour invasion and the histological type. For HGD or 
for intramucosal cancer, a systematic review of surgical literature, has reported 
that the rates of occult invasive cancer in patients undergoing esophagectomy for 
the treatment of HGD was 12.7% (pooled average in 441 patients from 23 studies)  
[67]. The rate of node positivity in high grade dysplasia and T1a cancers was 
estimated to be 0–2%. A retrospective review of 126 patients with T1 tumors of 
adenocarcinoma histology reported the rate of nodal involvement in T1a and T1b 
as 1.3–22%, respectively [64]. Data in early esophageal cancer has shown that 
M3 cancer (disease extending to the muscularis mucosa) has at least 6% risk of 
lymph metastases [63]. Additional characteristics which impact the risk of nodal 
involvement include vascular invasion, tumor size, and the degree of tumor dif-
ferentiation. Given the low risk of node positivity in early stage esophageal cancer 
confined to the mucosa, there is general consensus that endoscopic management 
is adequate and reliable for the treatment of mucosal disease (T1a). Endoscopic 
resection is, therefore, curative in such lesions. Initially, options included argon 
beam coagulation, laser, and photodynamic therapy. More recently, endoscopic 
mucosal resection (EMR), endoscopic submucosal dissection (ESD), radio-
frequency ablation (RFA), cryotherapy, and free-hand mucosal resection have 
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increasingly been applied [68]. However, data on these modalities of treatment are 
limited at present, and efficacy of one technique over another has not been estab-
lished [69].
However, all visible lesions should ideally be removed by EMR for definitive 
histopathological staging and to ensure adequacy of resection margins. This recom-
mendation is based on the poor accuracy of EUS to discriminate between T1a and 
T1b lesions. In this regard, EMR remains the sole technique able to stage the degree 
of invasion into the esophageal wall. For intramucosal cancer associated with 
Barrett’s esophagus, eradication of the metaplastic mucosa is essential to prevent 
the development of potentially malignant lesions. For segments that measure 
≤5 cm and harbor HGD or intramucosal cancer, an EMR approach is used. For 
patients with segments >5 cm, all focal lesions are resected with EMR or ESD and 
the residual base of the Barrett’s lesion radiofrequency ablated which reduces the 
incidence of stricture formation [68].
10.1.2 T1B and T2 tumors
As mentioned above, lymphatic invasion and hence, nodal involvement in T1a 
lesions is uncommon. However, once the muscularis mucosa is breached, dissemi-
nation of cancer cells can occur via the submucosal lymphatic plexus. Thus, T1b 
and T2 cancers have a disproportionately higher incidence of node positivity when 
compared to T1a cancers [64]. The depth of invasion beyond which an endoscopic 
resection is considered inadequate treatment remains controversial. In one clinical 
series, it was demonstrated that EMR could be performed in low grade submucosal 
SM1 lesions (considered ‘low risk’ tumors) [70]. At a mean follow-up of 5 years, 
no tumor related deaths were reported. However, according to other series, rate of 
node positivity in SM1 tumors is in the range of 16.5–21% [64, 71–73]. For tumors 
invading beyond SM1, existing literature suggests that the incidence of nodal 
involvement in patients with T1b cancer ranges from 21 to 50% [59, 74].
Also, in a review of outcomes for T2 lesions, the current approach to clinical 
staging correlated with the pathological stage in just 13% of patients of those 
inaccurately staged, 63% were overstaged and the rest, understaged. Based on these 
results, the recommendation for treatment of T2 lesions is to proceed with defini-
tive surgery as it is considered optimal in both patients who are overstaged and 
accurately staged.
With regard to T1b and T2 cancers, the general consensus is to proceed to 
surgical resection without neoadjuvant therapy [75]. Patients who are discovered to 
be understaged after esophagectomy can be considered for adjuvant therapy [76]. 
Indications for esophagectomy in early stage esophageal cancer include failures of 
endoscopic therapy and all incomplete endoscopic mucosal resections.
Invasion of tumour into the submucosa is now considered an indication for 
esophagectomy, although invasion into the superficial third of the submucosa 
does not carry the same risk of nodal metastasis as the deeper two thirds, and 
could be potentially treated endoscopically [77, 78]. Apart from tumor charac-
teristics, the treatment modality chosen may also be tailored according to the 
patient preferences and characteristics and the surgical or endoscopic expertise 
available. A vagal sparing esophagectomy has also been proposed recently as 
an alternative to conventional esophagectomy. This procedure, which involves 
resection of the esophagus from the mediastinum using a stripping device leav-
ing the vagi and the nodes intact, has been reported to offer several advantages 
in carefully selected patients including the preservation of meal size, gastric 
emptying and BMI [74, 79]. However, prospective data in support of this tech-
nique is not available.
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10.1.3 Indication of neoadjuvant therapy in early stage cancer
Surgery alone in the form of an esophagectomy remains the standard treat-
ment for early stage cancer. Data promoting the benefits of neoadjuvant treat-
ment for localized esophageal cancer is scant. The Fédération Francophone de la 
Cancérologie Digestive (FFCD) 9901 assessed whether preoperative chemoradio-
therapy (CRT) improved outcomes in patients with localized (stages I or II) esopha-
geal cancer [75]. From 2000 to 2009, 195 patients were randomized and assigned 
either to the surgery only group (n = 98) or to the neoadjuvant CRT group (n = 97).
Although postoperative morbidity rates were not statistically significant between 
the two groups, 30 day-mortality rates were 1.1% in the surgery alone group com-
pared to 7.3% in the CRT group (p = 0.054). At a median follow-up of 5.7 years, the 
median survival was 43.8 months in the surgery group compared to 31.8 months in 
the CRT group (HR 0.92; 95% confidence interval 0.63–1.34; p = 0.66). The trial 
concluded that neoadjuvant CRT with cisplatin and fluorouracil does not improve 
overall survival but increases postoperative mortality in patients with stage I and II 
esophageal cancer compared with surgery alone.
10.2 Locally advanced esophageal cancer
The vast majority of esophageal cancers are found to be locally advanced at 
presentation. Traditionally, both locally advanced esophageal SCC and adenocar-
cinoma have been managed with surgical resection. In this regard, esophagectomy 
with radical lymphadenectomy was considered to be the ideal treatment in terms of 
achieving local control. However, many patients developed locoregional recurrence 
or metastatic disease after surgery and survival was poor. Analyses of disease recur-
rence patterns and the dismal outcomes following surgery alone in this subset of 
patients of prompted the introduction of adjuvant treatment as a means of achiev-
ing locoregional control. However, esophagectomy being a major procedure with 
high morbidity, adjuvant therapy may not always be feasible and hence, manage-
ment strategies have now adopted neoadjuvant therapy. In some cases of carcinoma 
esophagus and more so in esophageal SCC, definitive CRT has been advocated as the 
first line treatment, taking into consideration the excellent response achievable by 
this modality. In these cases, surgery is reserved as a second line therapeutic option 
for patients in whom definitive CRT has failed (termed a “salvage” esophagectomy).
10.2.1 Neoadjuvant chemotherapy or chemoradiotherapy
Both neoadjuvant chemotherapy and radiotherapy are known to improve 
overall and disease free survival. They improve locoregional disease control by 
downstaging the cancer and improving resectability rates. Moreover, chemotherapy 
eradicates systemic micrometatstic disease by impeding the dissemination of 
cancer cells. Ameta-analysis by Gebski et al. evaluated outcomes associated with 
neoadjuvant chemotherapy and chemoradiotherapy followed by surgery compared 
to surgery alone in patients with locally resectable esophageal cancer regardless of 
the histological type [80]. The analysis included pooled data from 10 randomized 
controlled trials comparing surgery alone with neoadjuvant CRT and 8 random-
ized controlled trials comparing neoadjuvant chemotherapy with surgery. In the 
neoadjuvant chemotherapy group, the hazard ratio (HR) for all-cause mortality was 
0.90 (95% CI, 0.81–1.00; p = 0.05), indicating a 2-year absolute survival benefit 
of 7%. Survival benefit associated with neoadjuvant chemotherapy differed with 
the cancer histology: patients with SCC did not experience a survival benefit with 
neoadjuvant chemotherapy [HR for mortality 0.88 (0.75–1.03); p = 0.12] whereas 
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in the adenocarcinoma group, survival benefit was significant [HR for mortality 
0.78 (0.64–0.95); p = 0.014]. In the neoadjuvant chemoradiotherapy group, the HR 
for all-cause mortality was 0.81 (95% CI, 0.70–0.93; p = 0.002), corresponding to 
a 13% absolute difference in survival at 2 years when compared to surgery alone. 
With respect to tumour histology, neoadjuvant CRT was associated with a signifi-
cant benefit over surgery in both esophageal adenocarcinoma and squamous cell 
carcinoma [HR of 0.84 (0.71–0.99; p = 0.04) for SCC and 0.75 (0.59–0.95; p = 0.02) 
for adenocarcinoma].
The updated meta-analysis published by Sjoquist et al in 2011 included 4,188 
patients from the 17 studies evaluated in the previous meta-analysis with an addi-
tional seven more recent studies [81]. The inter-group analysis demonstrated strong 
arguments for CRT compared to CT in patients with SCC or adenocarcinoma. The 
HR for all-cause mortality for neoadjuvant chemotherapy was 0.87 (0.79–0.96; 
p = 0.005). When comparing the histological subtypes, the HR for SCC only was 
0.92 (0.81–1.04; p = 0.18) whereas that for adenocarcinoma was 0.83 (0.71–0.95; 
p = 0.01). The HR for all-cause mortality for neoadjuvant CRT was 0.78 (95% CI, 
0.70–0.88; p < 0.0001); that for SCC only was 0.80 (0.68–0.93; p = 0.004) and for 
adenocarcinoma, 0.75 (0.59–0.95; p = 0.02). When comparing all-cause mortality 
for neoadjuvant CRT versus neoadjuvant chemotherapy, the HR for the overall 
indirect comparison was 0.88 (0.76–1.01; p = 0.07).
However, the above meta-analysis did not include data from the recent phase 
III ‘CROSS’ trial which compared the outcomes associated with concurrent CRT 
(involving carboplatine and plaxitaxel with 41 Gy) followed by surgery and surgery 
alone [82]. A pathological complete response was noted in 47 of 161 patients (29%) 
who received neoadjuvant CRT followed by surgery. Despite the rate of postopera-
tive complications and in-hospital mortality being similar in both groups, the 
overall survival was significantly better in the CRT group [HR 0.657 (0.495–0.871; 
p = 0.003)]. Median OS was 49.4 months in the CRT followed by surgery group as 
against 24 months in the surgery alone group.
In conclusion, neoadjuvant CRT is strongly recommended and may be con-
sidered the standard of care in patients with locally advanced esophageal cancer 
compared to neoadjuvant chemotherapy alone. However, the optimal neoadjuvant 
treatment regimen has not been established yet, as the various trials conducted have 
employed different drugs, doses, and schedules of chemotherapy and radiotherapy.
10.2.2 CRT: sequential or concomitant?
Gebski et al, in their meta-analysis, concluded that there was no survival 
benefit of sequential CRT for patients with SCC [HR for mortality 0.9 (0.72–1.03); 
p = 0.18]; the results obtained in the sequential CRT group were similar to that of 
the neoadjuvant chemotherapy group [80]. Concomitant CRT in patients with SCC 
had a significant benefit [HR for mortality 0.76 (0.59–0.98); p = 0.04]. On this 
basis, concomitant CRT has been recommended in patients with locally advanced 
cancer of the esophagus planned for neoadjuvant therapy.
10.2.3 Neoadjuvant or adjuvant treatment?
This issue was addressed by the Japan Clinical Oncology Group which conducted 
two randomized controlled trials to assess potential benefits of adding adjuvant 
therapy to surgery in patients with SCC. The JCOG 9204 sought to identify the 
benefit associated with adjuvant cisplatin plus 5-FU when compared to surgery 
alone in patients with resectable stage I and II esophageal cancer [83]. Although 
overall survival was not significantly different between the two groups (5-year 
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survival rate 52 vs. 61%; p = 0.13), disease-free survival was significantly better in 
those receiving postoperative CT, especially in node positive disease. In the JCOG 
9907 study, neoadjuvant cisplatin and 5-FU was compared with adjuvant cisplatin 
plus 5-FU in patients with clinical stage II or III esophageal cancer [84]. In terms of 
overall survival, neoadjuvant CT was found to be superior with a 5-year survival 
rate of 60% compared to 38% in the adjuvant group (p = 0.013). Based on the 
results of these studies, neoadjuvant chemotherapy followed by radical surgery is 
currently recommended as the standard in locally advanced SCC.
10.2.4 Neoadjuvant CRT followed by surgery or definitive CRT?
Definitive CRT as a treatment modality in the management of esophageal cancer 
was introduced following the Radiation Therapy Oncology Group (RTOG) 8,501 
study [85]. This trial, which included both esophageal SCC and adenocarcinoma, 
compared outcomes after RT alone (64 Gy) with concurrent CRT (cisplatin, 5- FU, 
and radiotherapy 50 Gy). This study demonstrated the strong sensitivity of SCC 
to concomitant CRT which resulted in better overall survival and decreased local 
failure rates when compared to RT alone. Subsequently, a Japanese phase II trial 
analyzed the efficacy of definitive CRT (cisplatin and 5-FU with classic portal 
radiation 60 Gy) in squamous cell carcinoma of the esophagus [86]. Although a 
complete response was obtained in 68% with a 3-year survival rate of 46%, these 
results were not superior to those obtained with conventional surgical resection 
with or without chemotherapy. Among the trials conducted comparing definitive 
CRT with neoadjuvant CRT in esophageal SCC, the study performed by the German 
Esophageal Cancer Study Group reported that the 2-year overall survival was simi-
lar in the neoadjuvant CRT followed by surgery group (39.9%) and the definitive 
CRT treatment group (35.4%) [87]. The neoadjuvant therapy group was compli-
cated by a higher rate of early postoperative mortality, while definitive CRT was 
associated with a higher incidence of local relapses. These results were reproduced 
in another large randomized study, the FFCD-9102, where surgery was proposed in 
responders to CRT. Although surgery was reported to improve local control, it did 
not translate to an improvement in survival as neoadjuvant therapy was associated 
with increased early mortality [88].
On the basis on these results, both definitive CRT and neoadjuvant CRT followed 
by surgery seem to have similar long-term results. Despite flaws in these studies, 
surgery appears to provide better local control of the tumor but without any impact 
on long-term survival outcomes. Cost of major surgery and the risk of postoperative 
mortality are important factors that should be considered in patients being planned 
for neoadjuvant therapy followed by esophagectomy.
10.3 Salvage esophagectomy
In Japan and in Western countries, medical and radiation oncologists have 
reported satisfactory outcomes with definitive CRT blurring the boundaries of 
traditional treatment strategies. Definitive CRT is now considered a treatment 
option even in potentially resectable patients. Another factor favoring definitive 
CRT is that a complete response has been noted in the resected specimen in 15–30% 
of patients undergoing neoadjuvant therapy followed by surgery [81]. However, 
persistent disease and risk of local failure after definitive CRT remains a concern. 
It should be noted that locoregional morbidity need not always be related to the 
neoplastic process; local toxicity secondary to CRT or mechanical complications 
such as stricture formation may also be associated. Locoregional recurrence is 
defined as tumor detected more than 3 months after CRT whereas persistent 
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disease is the detection of malignancy within 3 months of CRT at the same site [89]. 
Unfortunately, locoregional control is often quite poor with definitive CRT, and 
up to 40–60% of the patients have persistent or relapsed tumor at the primary site 
within 1 year [88]. Moreover, due to radiotherapy associated fibrosis, histological 
confirmation of the malignancy is achievable in less than 60% of cases [90]. The 
prognosis is dismal in 11–26% of patients who do not exhibit any morphologic 
tumor response following definitive CRT (median survival of 9 months) [91]. 
Salvage esophagectomy is considered the only curative option for a subset of 
carefully selected patient who have received up to 50 Gy of radiation and who are 
physiologically fit for surgery. A number of studies have demonstrated the utility 
of salvage esophagectomy as a therapeutic option in recurrent or persistent disease 
following definitive CRT [90–98] with a subset of patients being cured after salvage 
esophagectomy with acceptable long-term outcomes. However, the decision to pro-
ceed with salvage esophagectomy is seldom straightforward considering the high 
postoperative morbidity and mortality associated with this procedure; each case 
must be evaluated individually. Initial studies examining the utilization of ‘salvage 
esophagectomy’ indicated that the procedure was associated with a significantly 
higher incidence of post-operative mortality, anastomotic leak, pulmonary compli-
cations and an increased length of ICU and in-hospital stay [89–99]. Much of this 
concern originated from the historical impression that surgical resection 4–8 weeks 
following radiotherapy or CRT was technically more challenging and associated 
with increased postoperative morbidity and mortality. This opinion has recently 
been challenged [100] with several publications demonstrating that the selected 
utilization of salvage esophagectomy in patients who have failed definitive CRT for 
esophageal SCC resulted in acceptable morbidity and mortality rates [89, 90, 94]. 
Special attention should be paid to the dose of radiation given: salvage surgery is 
considered highly morbid when the volume dose of radiation exceeds 55 Gy [90]. 
A randomized clinical trial assessing long-term outcomes indicated that definitive 
CRT could potentially cause progressive deterioration in pulmonary function when 
compared to surgery alone [100].
10.4 Minimally invasive esophagectomy (MIE)
MIE includes total thoraco-laparoscopic esophagectomy, robot-assisted mini-
mally invasive esophagectomy (RAMIE) and hybrid procedures. Over the last 
decades, MIE has expanded worldwide and is estimated that they account for 
15–30% of all esophagectomies performed at present [101, 102]. It seems likely that 
importance of MIE will exceed that of hybrid techniques. There are now centers 
that are publishing consecutive series of over 1000 minimally invasive procedures 
[103]. The approach to esophagectomy varies from center to center, and any deci-
sion regarding the surgical approach should be tailored according to individual 
physiologic and tumor-related issues in each patient [104].
11. Conclusions
Management of esophageal cancer has been refined since the last decades. 
Surgery continues to play a pivotal role in the treatment of the disease, either alone 
or in combination with multimodal approach. Progress in anesthesia and in surgery 
has led to a significant decrease in the mortality rate. Mortality rates average 5% and 
are under 2% in some experienced and high volume centers. The progress made in 
the field of minimal access surgery has led surgeons to consider these techniques 
to reduce the morbidity and mortality that have traditionally been associated with 
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surgery of the esophagus. Qualified surgeons with a high-level of expertise in high-
volume centers are essential in this context to ensure optimal outcomes.
12. Future perspective
Multimodality treatment involving the surgeon, gastroenterologist, oncologist 
(medical and radiotherapy), radiologist, pathologist, and palliative care physicians 
is fundamental in the management of esophageal cancer. This serves to individual-
ize treatment, optimize outcomes and ensure the best possible quality of life for the 
patients. Minimally invasive techniques have been proven to be noninferior to open 
surgery in terms of oncological safety and will benefit the patient in terms of post-
operative recovery. In future, advances in cancer genomics and gene testing can be 
expected identify key genetic and epigenetic alterations in cancers of the esophagus 
which initiate the growth and progression of disease. Identification of these genetic 
alterations may also result in the introduction of targeted therapies which may be 
individualized based on the molecular profile of the cancer.
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